Big Pharma has enjoyed an exceptional stretch of performance lately,
reversing what had been a relatively rare period of underperformance
brought on by overdone fears over this sector's ability to continue to
grow. While the recovery in Pfizer's (NYSE:PFE)
valuation was valid, the question now is whether the shares have
significant room left to move. Given a relatively weak growth profile,
investors shouldn't expect these strong returns to continue on all that
much longer.
Please continue here:
http://www.investopedia.com/stock-analysis/052113/after-big-rally-pfizer-might-need-some-rest-pfe-bmy-mrk-rhhby.aspx
No comments:
Post a Comment